| Olysio (simeprevir) / J&J, Medivir |
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Active, not recruiting | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
NCT02256176 / 2014-003446-27: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection |
|
|
| Not yet recruiting | 3 | 40 | Europe | Simeprevir, TMC435, Sofosbuvir | Janssen R&D Ireland, Janssen R&D Ireland | Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C | 11/15 | 01/16 | | |
NCT05728619: HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer |
|
|
| Recruiting | 1b/2 | 64 | RoW | HTMC0435, Temozolomide | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Recurrent Extensive Stage Small Cell Lung Carcinoma | 08/24 | 10/24 | | |
CTR20200573: Phase I/II clinical trial evaluating HTMC0435 tablets in patients with advanced malignant solid tumors |
|
|
| Recruiting | 1/2 | 42 | China | HTMC0435 - Shanghai Huilun | Shanghai Huilun Life Technology Co., Ltd./Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Avanced malignant solid tumors | | | | |